J.J.P. Kastelein - Concepedia

Author

J.J.P. Kastelein

Amsterdam UMC Location University of Amsterdam

Also Known As

J J Kastelein, J J P Kastelein, J J.P Kastelein, J KASTELEIN, J. A. Johnson, J. J P Kastelein, J. J. P. KASTELEIN, J. J. P. Kastelein, J.J. Kastelein, J.J.P. Kastelein

Publications

1.7K

Citations

H-Index

Concepts

All Affiliations

Amsterdam UMC Location University of Amsterdam University of Amsterdam University of British Columbia Radboud University Nijmegen University College London

About

J.J.P. Kastelein is an author at Amsterdam UMC Location University of Amsterdam specializing in medicine, atherosclerosis, and metabolic syndrome.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	8	8	353
2	Biochemistry	4	4	251
3	Public Health	3	3	65
4	Natural Sciences	2	2	26
5	Health Sciences	1	1	103

J.J.P. Kastelein

Publications

1.6K

Citations

H-Index

Page 1

	Year	Citations
Efficacy of statins in familial hypercholesterolaemia: a long term cohort study Jorie Versmissen, Daniëlla M. Oosterveer, Mojgan Yazdanpanah, BMJ	2008	711
Family history of premature coronary heart disease and risk prediction in the EPIC-Norfolk prospective population study Suthesh Sivapalaratnam, S. Matthijs Boekholdt, Mieke D. Trip, Heart	2010	123
A molecular defect causing fish eye disease: an amino acid exchange in lecithin-cholesterol acyltransferase (LCAT) leads to the selective loss of alpha-LCAT activity. Harald Funke, Arnold von Eckardstein, P. Haydn Pritchard, Proceedings of the National Academy of Sciences Ocular DiseaseFamily MembersGeneticsGenetic EpidemiologyPathology	1991	118
Inflammatory biomarkers, physical activity, waist circumference, and risk of future coronary heart disease in healthy men and women Jamal S. Rana, Benoît J. Arsenault, Jean‐Philippe Després, European Heart Journal	2009	115
The effect of concentrated n-3 fatty acids versus gemfibrozil on plasma lipoproteins, low density lipoprotein heterogeneity and oxidizability in patients with hypertrygliceridemia Anton F. H. Stalenhoef, Jacqueline de Graaf, Marianne E. Wittekoek, Atherosclerosis Metabolic SyndromeBiochemistryDiabetesPhysiologyHyperlipidemia	2000	103
Intensive Lipid Lowering With Atorvastatin in Patients With Coronary Artery Disease, Diabetes, and Chronic Kidney Disease James Shepherd, J.J.P. Kastelein, Vera Bittner, Mayo Clinic Proceedings Metabolic SyndromeIntensive LipidCardiovascular DiseaseMedicineChronic Kidney Disease	2008	62
Effects of Six <i>APOA5</i> Variants, Identified in Patients With Severe Hypertriglyceridemia, on In Vitro Lipoprotein Lipase Activity and Receptor Binding B. Dorfmeister, Weiwei Zeng, Andrea Dichlberger, Arteriosclerosis Thrombosis and Vascular Biology	2008	60
Increasing HDL cholesterol with extended-release nicotinic acid: from promise to practice. Rakesh S. Birjmohun, Barbara A. Hutten, J.J.P. Kastelein, PubMed	2004	54
Phenotypic Variation in Patients Heterozygous for Familial Defective Apolipoprotein B (FDB) in Three European Countries Peter S. Hansen, J.C. Defesche, J.J.P. Kastelein, Arteriosclerosis Thrombosis and Vascular Biology	1997	45
Rationale, Design and Baseline Characteristics of a Clinical Trial Comparing the Effects of Robust vs Conventional Cholesterol Lowering and Intima Media Thickness in Patients with Familial Hypercholesterolaemia Tineke J. Smilde, Mieke D. Trip, Hub Wollersheim, Clinical Drug Investigation Conventional Cholesterol LoweringMetabolic SyndromeLipid DisorderCardiovascular DiseaseHealth Policy	2000	33

Page 1